Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Gregory Lanza
Washington University, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Capella Imaging
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Based on WU’s Research COI Policy and the Procedures for Determining and Managing Research Financial Conflicts of Interests, the CIRC determined Dr. Lanza’s personal financial relationship with (b)(4), related to the above referenced research, creates a financial conflict of interest due to the following reasons:
• The primary focus of Capella Imaging, an entity with which Dr. Lanza owns equity, is to commercialize his IP being evaluated in the research listed above.
• Dr. Lanza’s role, as described below, could affect various aspects of the study.
While the CIRC determined Dr. Lanza has a financial conflict of interest, there are mitigating factors that help address the situation.
• There is currently no active license for the IP being evaluated and the committee understands the company has opted to not pursue a license for the IP while Dr. Lanza is actively involved in the research (listed above) at Washington University.
• For the human study, HRPO #201310123:
o The research presents minimal risk to patients, as it is a non-invasive imaging procedure
o There is no consent involved, as consenting was obtained through the repository study, HRPO #201104172, a study with which you have no role
• Dr. Lanza is uniquely qualified by virtue of his expertise and experience due to his unique understanding of the software and correlating it to the needs of occupational therapists. The research could not be conducted as efficiently or effectively without your involvement.
• Additionally, a plan has been developed to mitigate Dr. Lanza’s financial conflict of interest, which is outlined below.
DIAGNOSIS OF LEFT VENTRICULAR ASSIST DEVICE INTRAPUMP THROMBOSIS
Despite the myriad major advances in cardiology, the prognosis for patients with severe, medically refractive HF is exceeding poor. Left ventricular assist devices (LVAD), a mechanical circulatory support system, have developed tremendously and offer considerable hope and benefit to patients with severe HF. However, they are associated with gastrointestinal (GI) bleeding, driveline infections, and thrombotic complications. Successful LVAD outcomes require careful management of anticoagulation and the complex interplay between increased bleeding and prevention of intrapump thrombus. Unfortunately, multicenter efforts to lower anticoagulation goals to minimize bleeding complications resulted in a tripled incidence of pump thrombotic complications. Intra-pump thrombus cannot be directly diagnosed but only inferred from nonspecific evidence and these suggestive markers of pump thrombus are late findings. Intrapump thrombus detected earlier may be responsive to anti-thrombotic treatment or progression stabilized by improved anticoagulation. Ultimately early recognition and clinical intervention could thrombotic complications and minimize surgical pump exchanges. In light of the increasing need and utilization of LVADs, we developed a novel, fibrin-specific 99mTc small tetrameric molecule agent (99mTc-F4A) able to bind to native thrombus under the high shear and high flow conditions of the axial flow pumps (9,000RPM - 5L/min). 99mTc-F4A clears rapidly into urine, has negligible serum interference, and has excellent detectability through the titanium pump's housing and cannulas.
Filed on February 09, 2018.
Tell us what you know about Gregory Lanza's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.